Cargando…
Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome
INTRODUCTION: We investigated whether mRNA levels of E2F1, a key transcription factor involved in proliferation, differentiation and apoptosis, could be used as a surrogate marker for the determination of breast cancer outcome. METHODS: E2F1 and other proliferation markers were measured by quantitat...
Autores principales: | Vuaroqueaux, Vincent, Urban, Patrick, Labuhn, Martin, Delorenzi, Mauro, Wirapati, Pratyaksha, Benz, Christopher C, Flury, Renata, Dieterich, Holger, Spyratos, Frédérique, Eppenberger, Urs, Eppenberger-Castori, Serenella |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1929097/ https://www.ncbi.nlm.nih.gov/pubmed/17535433 http://dx.doi.org/10.1186/bcr1681 |
Ejemplares similares
-
Increased level of phosphorylated akt measured by chemiluminescence-linked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2
por: Cicenas, Jonas, et al.
Publicado: (2005) -
Comparison of gene expression profiles in core biopsies and corresponding surgical breast cancer samples
por: Zanetti-Dällenbach, Rosanna, et al.
Publicado: (2006) -
Increased Level of Phosphorylated ShcA Measured by Chemiluminescence-Linked Immunoassay Is a Predictor of Good Prognosis in Primary Breast Cancer Expressing Low Levels of Estrogen Receptor
por: Cicenas, Jonas, et al.
Publicado: (2010) -
CDO1 Promoter Methylation is a Biomarker for Outcome Prediction of Anthracycline Treated, Estrogen Receptor-Positive, Lymph Node-Positive Breast Cancer Patients
por: Dietrich, Dimo, et al.
Publicado: (2010) -
Enhanced NFκB and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer
por: Zhou, Yamei, et al.
Publicado: (2007)